Add like
Add dislike
Add to saved papers

Results of double Low-Profile Visualized Intraluminal Support (LVIS) Blue stenting for the treatment of fusiform cerebral aneurysms.

World Neurosurgery 2022 November 13
BACKGROUND: The flow diversion technique is increasingly used for reconstructive endovascular treatment of fusiform cerebral aneurysms. Double stenting with the Low-profile Visualized Intraluminal Support (LVIS) Blue stent is one of the flow diversion techniques. The aim of this study was to analyze the clinical and angiographic outcomes of LVIS Blue double stenting for fusiform cerebral aneurysms.

METHODS: Between March 2016 and July 2020, double LVIS Blue stenting was attempted in 25 fusiform cerebral aneurysms. Patient medical records and radiological images were carefully reviewed.

RESULTS: The technical success rate was 100% (25/25). Six aneurysms (24.0%) were located in the anterior circulation and 19 aneurysms (76.0%) were located in the posterior circulation. Intraprocedural thromboembolic complications occurred in 1 patient (4.0%). During the follow-up period (30.8 ± 14.2 months), there were no deaths or delayed complications. The mean angiographic follow-up duration was 28.2 ± 12.8 months. Follow-up angiography revealed complete obliteration (O'Kelly-Marotta [OKM] D) in 21 (84.0%) patients and near-complete obliteration (OKM C+2 matched with Kamran-Byrne grade 3) in 2 (8.0%) patients. Two patients (8.0%) showed worsening of obliteration grades. One (4.0%) patient required retreatment. There was no significant in-stent stenosis or branch occlusion covered by stents.

CONCLUSIONS: Double stenting using LVIS Blue stents for the treatment of fusiform cerebral aneurysms is effective and safe.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app